George A. Scangos - Feb 23, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 23, 2023
Transactions value $
-$680,747
Form type
4
Date filed
2/24/2023, 07:34 PM
Previous filing
Feb 21, 2023
Next filing
Mar 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Sale -$328K -12.6K -6.44% $25.97 184K Feb 23, 2023 Direct F1
transaction VIR Common Stock Sale -$96.4K -4.24K -2.31% $22.74 179K Feb 24, 2023 Direct F2, F3
transaction VIR Common Stock Sale -$256K -10.9K -6.07% $23.56 168K Feb 24, 2023 Direct F2, F4
holding VIR Common Stock 3.53M Feb 23, 2023 See footnote F5
holding VIR Common Stock 180K Feb 23, 2023 See footnote F6
holding VIR Common Stock 112K Feb 23, 2023 See footnote F7
holding VIR Common Stock 827K Feb 23, 2023 See footnote F8
holding VIR Common Stock 112K Feb 23, 2023 See footnote F9
holding VIR Common Stock 827K Feb 23, 2023 See footnote F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F2 Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.195 to $23.160 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.215 to $24.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F6 The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
F7 The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F8 The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F9 The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F10 The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.